{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T18:22:30Z","timestamp":1794075750036,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sarcopenia, a condition marked by progressive muscle mass and function decline, presents significant challenges in aging populations and those with chronic illnesses. Current standard treatments such as dietary interventions and exercise programs are often unsustainable. There is increasing interest in pharmacological interventions like bimagrumab, a monoclonal antibody that promotes muscle hypertrophy by inhibiting muscle atrophy ligands. Bimagrumab has shown effectiveness in various conditions, including sarcopenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The primary objective of this meta-analysis is to evaluate the impact of bimagrumab treatment on both physical performance and body composition among patients diagnosed with sarcopenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This meta-analysis follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We systematically searched PubMed, Ovid\/Medline, Web of Science, and the Cochrane Library databases up to June 2024 using appropriate Medical Subject Headings (MeSH) terms and keywords related to bimagrumab and sarcopenia. Eligible studies were randomized controlled trials (RCTs) that assessed the effects of bimagrumab on physical performance (e.g., muscle strength, gait speed, six-minute walk distance) and body composition (e.g., muscle volume, fat-free body mass, fat body mass) in patients with sarcopenia. Data extraction was independently performed by two reviewers using a standardized form, with discrepancies resolved through discussion or consultation with a third reviewer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From an initial search yielding 46 records, we screened titles, abstracts, and full texts to include seven RCTs in our meta-analysis. Bimagrumab treatment significantly increased thigh muscle volume (mean difference [MD] 5.29%, 95% confidence interval [CI] 4.08% to 6.50%, P\u2009&lt;\u20090.001; moderate heterogeneity \u03c72\u2009=\u20096.41, I2\u2009=\u200938%, P\u2009=\u20090.17) and fat-free body mass (MD 1.90 kg, 95% CI 1.57 kg to 2.23 kg, P\u2009&lt;\u20090.001; moderate heterogeneity \u03c72\u2009=\u20098.60, I2\u2009=\u200930%, P\u2009=\u20090.20), while decreasing fat body mass compared to placebo (MD \u2212\u00a04.55 kg, 95% CI \u2212\u00a05.08 kg to \u2212\u00a04.01\u00a0kg, P\u2009&lt;\u20090.001; substantial heterogeneity \u03c72\u2009=\u200927.44, I2\u2009=\u200989%, P\u2009&lt;\u20090.001). However, no significant improvement was observed in muscle strength or physical performance measures such as gait speed and six-minute walk distance with bimagrumab treatment, except among participants with slower baseline walking speeds or distances.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and conclusion<\/jats:title>\n                    <jats:p>This meta-analysis provides valuable insights into the effects of bimagrumab on sarcopenic patients, highlighting its significant improvements in body composition parameters but limited impact on functional outcomes. The observed heterogeneity in outcomes across studies underscores the need for cautious interpretation, considering variations in study populations, treatment durations, and outcome assessments. While bimagrumab shows promise as a safe pharmacological intervention for enhancing muscle mass and reducing fat mass in sarcopenia, its minimal effects on muscle strength and broader physical performance suggest potential limitations in translating body composition improvements into functional gains. Further research is needed to clarify its long-term efficacy, optimal dosing regimens, and potential benefits for specific subgroups of sarcopenic patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40520-024-02825-4","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T15:02:20Z","timestamp":1725894140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Effect of Bimagrumab on body composition: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"36","author":[{"given":"Mehmet","family":"Kanbay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrie","family":"Siriopol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidar","family":"Copur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuri Baris","family":"Hasbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"G\u00fcldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kam","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Garfias-Veitl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"2825_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16\u201331","journal-title":"Age Ageing"},{"key":"2825_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155533","volume":"144","author":"S Yuan","year":"2023","unstructured":"Yuan S, Larsson SC (2023) Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. Metabolism 144:155533","journal-title":"Metabolism"},{"key":"2825_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/nu12051293","author":"SK Papadopoulou","year":"2020","unstructured":"Papadopoulou SK (2020) Sarcopenia: A Contemporary Health Problem among Older Adult Populations. Nutrients. https:\/\/doi.org\/10.3390\/nu12051293","journal-title":"Nutrients"},{"key":"2825_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/rco2.9","author":"J Ishida","year":"2020","unstructured":"Ishida J, Saitoh M, Ebner N et al (2020) Growth hormone secretagogues: history, mechanism of action, and clinical development. JCMS rapid commun. https:\/\/doi.org\/10.1002\/rco2.9","journal-title":"JCMS rapid commun"},{"key":"2825_CR5","doi-asserted-by":"publisher","DOI":"10.17987\/jcsm-cr.v2i1.37","author":"M Saitoh","year":"2017","unstructured":"Saitoh M, Ishida J, Ebner N et al (2017) Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy. JCSM Clinic Rep. https:\/\/doi.org\/10.17987\/jcsm-cr.v2i1.37","journal-title":"JCSM Clinic Rep"},{"key":"2825_CR6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1128\/MCB.01307-13","volume":"34","author":"E Lach-Trifilieff","year":"2014","unstructured":"Lach-Trifilieff E, Minetti GC, Sheppard K et al (2014) An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol 34:606\u2013618","journal-title":"Mol Cell Biol"},{"key":"2825_CR7","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/jgs.14927","volume":"65","author":"D Rooks","year":"2017","unstructured":"Rooks D, Praestgaard J, Hariry S et al (2017) Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled proof concept study. J Am Geriatr Soc 65:1988\u20131995","journal-title":"J Am Geriatr Soc"},{"key":"2825_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/jcsm.12205","volume":"8","author":"DS Rooks","year":"2017","unstructured":"Rooks DS, Laurent D, Praestgaard J et al (2017) Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy. J Cachexia Sarcopenia Muscle 8:727\u2013734","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2825_CR9","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","volume":"18","author":"MG Hanna","year":"2019","unstructured":"Hanna MG, Badrising UA, Benveniste O et al (2019) Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol 18:834\u2013844","journal-title":"Lancet Neurol"},{"key":"2825_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.20836","volume":"3","author":"D Rooks","year":"2020","unstructured":"Rooks D, Swan T, Goswami B et al (2020) Bimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults: a randomized clinical trial. JAMA Netw Open 3:e2020836","journal-title":"JAMA Netw Open"},{"key":"2825_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1164\/rccm.201802-0286OC","volume":"199","author":"MI Polkey","year":"2019","unstructured":"Polkey MI, Praestgaard J, Berwick A et al (2019) Activin type II receptor blockade for treatment of muscle depletion in chronic obstructive pulmonary disease. A randomized Trial. Am J Respir Crit Care Med 199:313\u2013320. https:\/\/doi.org\/10.1164\/rccm.201802-0286OC","journal-title":"Am J Respir Crit Care Med"},{"key":"2825_CR12","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/S2666-7568(21)00084-2","volume":"2","author":"LC Hofbauer","year":"2021","unstructured":"Hofbauer LC, Witvrouw R, Varga Z et al (2021) Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a\/b trial. Lancet Healthy Longev 2:e263\u2013e274","journal-title":"Lancet Healthy Longev"},{"key":"2825_CR13","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa040933","volume":"350","author":"M Schuelke","year":"2004","unstructured":"Schuelke M, Wagner KR, Stolz LE et al (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350:2682\u20132688","journal-title":"N Engl J Med"},{"key":"2825_CR14","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1101\/gr.7.9.910","volume":"7","author":"R Kambadur","year":"1997","unstructured":"Kambadur R, Sharma M, Smith TP et al (1997) Mutations in myostatin (GDF8) in double-muscled belgian blue and piedmontese cattle. Genome Res 7:910\u2013916","journal-title":"Genome Res"},{"key":"2825_CR15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1-34","journal-title":"J Clin Epidemiol"},{"key":"2825_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jclinepi.2021.04.012","volume":"137","author":"AI Dobrescu","year":"2021","unstructured":"Dobrescu AI, Nussbaumer-Streit B, Klerings I et al (2021) Restricting evidence syntheses of interventions to english-language publications is a viable methodological shortcut for most medical topics: a systematic review. J Clin Epidemiol 137:209\u2013217","journal-title":"J Clin Epidemiol"},{"key":"2825_CR17","unstructured":"Higgins JPT TJ. Handbook for Systematic Reviews of Interventions. https:\/\/handbook-5-1.cochrane.org\/chapter_7\/7_7_3_2_obtaining_standard_deviations_from_standard_errors_and.htm. Accessed 16 July 2024"},{"key":"2825_CR18","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1002\/jcsm.12639","volume":"11","author":"D Rooks","year":"2020","unstructured":"Rooks D, Petricoul O, Praestgaard J et al (2020) Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort. J Cachexia Sarcopenia Muscle 11:1525\u20131534","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2825_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield SB, Coleman LA, Miller R et al (2021) Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open 4:e2033457","journal-title":"JAMA Netw Open"},{"key":"2825_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/jcsm.12073","volume":"7","author":"JC Brown","year":"2016","unstructured":"Brown JC, Harhay MO, Harhay MN (2016) Sarcopenia and mortality among a population-based sample of community-dwelling older adults. J Cachexia sarcopenia Muscle 7:290\u2013298","journal-title":"J Cachexia sarcopenia Muscle"},{"key":"2825_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/ggi.12723","volume":"16","author":"H Kim","year":"2016","unstructured":"Kim H, Hirano H, Edahiro A et al (2016) Sarcopenia: prevalence and associated factors based on different suggested definitions in community-dwelling older adults. Geriatr Gerontol Int 16:110\u2013122","journal-title":"Geriatr Gerontol Int"},{"key":"2825_CR22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/ageing\/afs197","volume":"42","author":"HP Patel","year":"2013","unstructured":"Patel HP, Syddall HE, Jameson K et al (2013) Prevalence of sarcopenia in community-dwelling older people in the UK using the European working group on sarcopenia in older people (EWGSOP) definition: findings from the hertfordshire cohort study (HCS). Age Ageing 42:378\u2013384","journal-title":"Age Ageing"},{"key":"2825_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cger.2016.08.002","volume":"33","author":"RJ Dhillon","year":"2017","unstructured":"Dhillon RJ, Hasni S (2017) Pathogenesis and management of sarcopenia. Clin Geriatr Med 33:17\u201326","journal-title":"Clin Geriatr Med"},{"key":"2825_CR24","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a029785","author":"G Distefano","year":"2018","unstructured":"Distefano G, Goodpaster BH (2018) Effects of exercise and aging on skeletal Muscle. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a029785","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2825_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/nu15184073","author":"C Tezze","year":"2023","unstructured":"Tezze C, Sandri M, Tessari P (2023) Anabolic resistance in the pathogenesis of sarcopenia in the elderly: role of nutrition and exercise in young and old people. Nutrients. https:\/\/doi.org\/10.3390\/nu15184073","journal-title":"Nutrients"},{"key":"2825_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/nu15204335","author":"J Liu","year":"2023","unstructured":"Liu J, Zhu Y, Tan JK et al (2023) Factors associated with sarcopenia among elderly individuals residing in community and nursing home settings: a systematic review with a meta-analysis. Nutrients. https:\/\/doi.org\/10.3390\/nu15204335","journal-title":"Nutrients"},{"key":"2825_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/CIA.S438144","volume":"19","author":"H Ooi","year":"2024","unstructured":"Ooi H, Welch C (2024) Obstacles to the early diagnosis and management of sarcopenia: current perspectives. Clin Interv Aging 19:323\u2013332","journal-title":"Clin Interv Aging"},{"key":"2825_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2021.04.001","volume":"60","author":"A Lodberg","year":"2021","unstructured":"Lodberg A (2021) Principles of the activin receptor signaling pathway and its inhibition. Cytokine Growth Fact Rev 60:1\u201317","journal-title":"Cytokine Growth Fact Rev"},{"key":"2825_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13395-015-0060-8","volume":"5","author":"E Latres","year":"2015","unstructured":"Latres E, Pangilinan J, Miloscio L et al (2015) Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet Muscle 5:34","journal-title":"Skelet Muscle"},{"key":"2825_CR30","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","volume":"3","author":"C Becker","year":"2015","unstructured":"Becker C, Lord SR, Studenski SA et al (2015) Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabet Endocrinol 3:948\u2013957","journal-title":"Lancet Diabet Endocrinol"},{"key":"2825_CR31","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/cpdd.386","volume":"7","author":"I Bhattacharya","year":"2018","unstructured":"Bhattacharya I, Pawlak S, Marraffino S et al (2018) Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an antimyostatin monoclonal antibody. Healthy Subj Clin Pharmacol Drug Dev 7:484\u2013497","journal-title":"Healthy Subj Clin Pharmacol Drug Dev"},{"key":"2825_CR32","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/mus.23539","volume":"47","author":"KM Attie","year":"2013","unstructured":"Attie KM, Borgstein NG, Yang Y et al (2013) A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve 47:416\u2013423","journal-title":"Muscle Nerve"},{"key":"2825_CR33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/dom.13042","volume":"20","author":"T Garito","year":"2018","unstructured":"Garito T, Roubenoff R, Hompesch M et al (2018) Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals. Diab Obes Metab 20:94\u2013102","journal-title":"Diab Obes Metab"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-024-02825-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-024-02825-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-024-02825-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T15:30:14Z","timestamp":1725895814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-024-02825-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2825"],"URL":"https:\/\/doi.org\/10.1007\/s40520-024-02825-4","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Kalantar has received honoraria from Fresenius, DaVita, CSL, GSK. Dr. S.v.H. has been a paid consultant for and\/or received honoraria payments from Amomed, AstraZeneca, Bayer, Boehringer Ingelheim, BRAHMS, Edwards Lifesciences, MSD, Novartis, Pfizer, Pharmacosmos, Respicardia, Roche, Servier, Sorin, and Vifor. S.v.H. reports research support from Amgen, AstraZeneca, Boehringer Ingelheim, Pharmacosmos, IMI, and the German Center for Cardiovascular Research (DZHK). Other Authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"185"}}